Pieris Ebitda vs Net Income From Continuing Ops Analysis

PIRS Stock

USD 11.25 0.12 1.06%

Pieris Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pieris Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pieris Pharmaceuticals is a good investment. Please check the relationship between Pieris Pharmaceuticals Ebitda and its Net Income From Continuing Ops accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

Ebitda vs Net Income From Continuing Ops

Ebitda vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pieris Pharmaceuticals Ebitda account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Pieris Pharmaceuticals' Ebitda and Net Income From Continuing Ops is 0.94. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Pieris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pieris Pharmaceuticals' Ebitda and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Pieris Pharmaceuticals are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Ebitda i.e., Pieris Pharmaceuticals' Ebitda and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Ebitda

Net Income From Continuing Ops

Most indicators from Pieris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.At this time, Pieris Pharmaceuticals' Issuance Of Capital Stock is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.07 in 2024, whereas Selling General Administrative is likely to drop slightly above 13.5 M in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	31.4M	25.9M	42.8M	25.4M
Depreciation And Amortization	3.7M	8.2M	1.8M	1.9M

Total Revenue Depreciation And Amortization

Pieris Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Other Assets	Net Receivables	Retained Earnings Total Equity	Short Term Investments
Total Assets		0.73	0.73	0.91	0.82	-0.9	-0.56	0.92	0.99	0.73	0.81	0.91	0.97	0.97	0.09	0.64	0.9	0.8	0.62	0.74	0.81	0.69	0.55	0.5	-0.71	0.65
Short Long Term Debt Total	0.73		0.58	0.64	0.77	-0.67	-0.65	0.66	0.71	0.86	0.61	0.7	0.64	0.73	0.55	0.78	0.67	0.77	0.53	0.63	0.57	0.6	0.52	0.48	-0.73	0.48
Other Current Liab	0.73	0.58		0.74	0.76	-0.77	-0.81	0.78	0.71	0.85	0.59	0.68	0.64	0.74	-0.1	0.82	0.59	0.77	0.73	0.64	0.71	0.7	0.56	0.21	-0.86	0.28
Total Current Liabilities	0.91	0.64	0.74		0.65	-0.82	-0.61	0.8	0.89	0.69	0.71	0.85	0.93	0.93	0.12	0.62	0.89	0.64	0.48	0.9	0.67	0.59	0.37	0.63	-0.71	0.68
Total Stockholder Equity	0.82	0.77	0.76	0.65		-0.82	-0.68	0.84	0.82	0.78	0.6	0.73	0.67	0.84	0.17	0.76	0.68	1.0	0.66	0.49	0.86	0.65	0.56	0.2	-0.79	0.44
Net Debt	-0.9	-0.67	-0.77	-0.82	-0.82		0.48	-0.98	-0.92	-0.65	-0.73	-0.75	-0.84	-0.89	-0.16	-0.58	-0.75	-0.8	-0.5	-0.63	-0.71	-0.54	-0.46	-0.24	0.65	-0.39
Retained Earnings	-0.56	-0.65	-0.81	-0.61	-0.68	0.48		-0.51	-0.49	-0.89	-0.32	-0.68	-0.46	-0.62	-0.01	-0.93	-0.57	-0.72	-0.82	-0.63	-0.64	-0.82	-0.69	-0.42	0.97	-0.29
Cash	0.92	0.66	0.78	0.8	0.84	-0.98	-0.51		0.93	0.67	0.78	0.78	0.87	0.89	0.09	0.59	0.75	0.81	0.59	0.59	0.76	0.63	0.56	0.23	-0.68	0.36
Cash And Short Term Investments	0.99	0.71	0.71	0.89	0.82	-0.92	-0.49	0.93		0.68	0.78	0.88	0.95	0.97	0.09	0.59	0.9	0.8	0.52	0.74	0.77	0.59	0.46	0.43	-0.65	0.68
Common Stock Total Equity	0.73	0.86	0.85	0.69	0.78	-0.65	-0.89	0.67	0.68		0.56	0.75	0.63	0.73	0.21	0.97	0.66	0.81	0.79	0.71	0.69	0.81	0.66	0.48	-0.93	0.39
Common Stock Shares Outstanding	0.81	0.61	0.59	0.71	0.6	-0.73	-0.32	0.78	0.78	0.56		0.57	0.81	0.71	0.21	0.42	0.55	0.55	0.43	0.44	0.55	0.46	0.42	0.27	-0.51	0.39
Non Current Liabilities Total	0.91	0.7	0.68	0.85	0.73	-0.75	-0.68	0.78	0.88	0.75	0.57		0.9	0.92	-0.05	0.7	0.97	0.74	0.74	0.8	0.79	0.82	0.68	0.61	-0.77	0.68
Total Liab	0.97	0.64	0.64	0.93	0.67	-0.84	-0.46	0.87	0.95	0.63	0.81	0.9		0.93	0.05	0.53	0.91	0.64	0.54	0.77	0.71	0.64	0.49	0.57	-0.62	0.68
Total Current Assets	0.97	0.73	0.74	0.93	0.84	-0.89	-0.62	0.89	0.97	0.73	0.71	0.92	0.93		0.11	0.66	0.93	0.83	0.56	0.8	0.8	0.64	0.48	0.51	-0.74	0.72
Short Term Debt	0.09	0.55	-0.1	0.12	0.17	-0.16	-0.01	0.09	0.09	0.21	0.21	-0.05	0.05	0.11		0.18	0.03	0.16	-0.24	0.16	-0.05	-0.13	-0.21	0.34	-0.08	0.04
Common Stock	0.64	0.78	0.82	0.62	0.76	-0.58	-0.93	0.59	0.59	0.97	0.42	0.7	0.53	0.66	0.18		0.6	0.8	0.78	0.68	0.65	0.79	0.64	0.46	-0.94	0.35
Other Liab	0.9	0.67	0.59	0.89	0.68	-0.75	-0.57	0.75	0.9	0.66	0.55	0.97	0.91	0.93	0.03	0.6		0.67	0.56	0.85	0.71	0.67	0.52	0.65	-0.67	0.78
Net Tangible Assets	0.8	0.77	0.77	0.64	1.0	-0.8	-0.72	0.81	0.8	0.81	0.55	0.74	0.64	0.83	0.16	0.8	0.67		0.68	0.5	0.86	0.67	0.57	0.22	-0.82	0.43
Property Plant And Equipment Net	0.62	0.53	0.73	0.48	0.66	-0.5	-0.82	0.59	0.52	0.79	0.43	0.74	0.54	0.56	-0.24	0.78	0.56	0.68		0.41	0.74	0.97	0.91	0.3	-0.85	0.16
Current Deferred Revenue	0.74	0.63	0.64	0.9	0.49	-0.63	-0.63	0.59	0.74	0.71	0.44	0.8	0.77	0.8	0.16	0.68	0.85	0.5	0.41		0.46	0.54	0.31	0.75	-0.67	0.7
Accounts Payable	0.81	0.57	0.71	0.67	0.86	-0.71	-0.64	0.76	0.77	0.69	0.55	0.79	0.71	0.8	-0.05	0.65	0.71	0.86	0.74	0.46		0.76	0.53	0.38	-0.73	0.46
Non Current Assets Total	0.69	0.6	0.7	0.59	0.65	-0.54	-0.82	0.63	0.59	0.81	0.46	0.82	0.64	0.64	-0.13	0.79	0.67	0.67	0.97	0.54	0.76		0.88	0.49	-0.86	0.26
Other Assets	0.55	0.52	0.56	0.37	0.56	-0.46	-0.69	0.56	0.46	0.66	0.42	0.68	0.49	0.48	-0.21	0.64	0.52	0.57	0.91	0.31	0.53	0.88		0.15	-0.74	0.07
Net Receivables	0.5	0.48	0.21	0.63	0.2	-0.24	-0.42	0.23	0.43	0.48	0.27	0.61	0.57	0.51	0.34	0.46	0.65	0.22	0.3	0.75	0.38	0.49	0.15		-0.43	0.61
Retained Earnings Total Equity	-0.71	-0.73	-0.86	-0.71	-0.79	0.65	0.97	-0.68	-0.65	-0.93	-0.51	-0.77	-0.62	-0.74	-0.08	-0.94	-0.67	-0.82	-0.85	-0.67	-0.73	-0.86	-0.74	-0.43		-0.34
Short Term Investments	0.65	0.48	0.28	0.68	0.44	-0.39	-0.29	0.36	0.68	0.39	0.39	0.68	0.68	0.72	0.04	0.35	0.78	0.43	0.16	0.7	0.46	0.26	0.07	0.61	-0.34

Click cells to compare fundamentals

Pieris Pharmaceuticals Account Relationship Matchups

Pieris Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Other Current Liab	5.0M	5.5M	15.8M	10.7M	8.6M	5.7M
Total Current Liabilities	27.0M	22.1M	50.6M	36.6M	11.9M	23.7M
Total Stockholder Equity	51.4M	31.0M	50.8M	27.9M	26.8M	28.8M
Net Debt	(46.0M)	(53.5M)	(103.9M)	(25.5M)	(17.4M)	(18.3M)
Retained Earnings	(174.2M)	(211.4M)	(257.1M)	(290.4M)	(315.0M)	(299.2M)
Cash	62.3M	70.4M	117.8M	38.6M	17.4M	16.5M
Cash And Short Term Investments	104.2M	70.4M	117.8M	59.2M	26.4M	25.0M
Common Stock Total Equity	54K	55K	56K	72K	82.8K	42.7K
Common Stock Shares Outstanding	50.6M	54.5M	64.5M	74.2M	1.1M	1.1M
Liabilities And Stockholders Equity	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Non Current Liabilities Total	62.7M	51.8M	52.2M	31.0M	35.6M	30.4M
Total Liab	89.7M	74.0M	102.8M	67.6M	11.9M	11.3M
Total Current Assets	115.0M	75.7M	127.6M	73.4M	38.7M	68.3M
Common Stock	55K	56K	72K	74K	98K	53.4K
Other Liab	47.3M	35.9M	38.4M	18.7M	21.5M	26.7M
Net Tangible Assets	51.4M	31.0M	50.8M	27.9M	32.1M	31.6M
Property Plant And Equipment Net	22.9M	26.0M	23.0M	20.7M	23.8M	12.2M
Current Deferred Revenue	11.3M	12.6M	25.1M	20.8M	23.9M	17.9M
Accounts Payable	10.1M	3.0M	8.6M	4.2M	3.4M	4.0M
Non Current Assets Total	26.1M	29.3M	25.9M	22.1M	25.4M	14.6M
Other Assets	910K	3.1M	7.2M	2.9M	3.3M	1.8M
Net Receivables	6.8M	1.7M	3.3M	5.8M	6.0M	4.4M
Retained Earnings Total Equity	(147.1M)	(174.2M)	(211.4M)	(257.1M)	(231.4M)	(219.9M)
Short Term Investments	34.8M	53.2M	41.9M	20.5M	9.0M	15.9M
Capital Surpluse	189.9M	227.5M	242.7M	307.0M	353.0M	370.7M
Other Current Assets	4.1M	3.6M	6.5M	8.4M	6.3M	4.3M
Other Stockholder Equity	227.5M	242.7M	307.0M	318.5M	341.6M	214.7M
Property Plant And Equipment Gross	22.9M	22.0M	23.0M	20.7M	23.8M	25.0M
Accumulated Other Comprehensive Income	(2.0M)	(295K)	829K	(254K)	28K	29.4K
Non Current Liabilities Other	27K	62.7M	6K	52.2M	60.1M	63.1M
Property Plant Equipment	19.5M	26.0M	23.0M	20.7M	23.8M	25.0M
Non Currrent Assets Other	3.1M	3.3M	2.9M	1.4M	1.6M	1.7M
Net Invested Capital	51.4M	31.0M	50.8M	27.9M	32.1M	39.0M
Net Working Capital	88.0M	53.6M	77.1M	36.8M	33.2M	51.6M
Capital Stock	55K	56K	72K	74K	85.1K	68.4K

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pieris Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Pieris Pharmaceuticals is a strong investment it is important to analyze Pieris Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pieris Pharmaceuticals' future performance. For an informed investment choice regarding Pieris Stock, refer to the following important reports:

How To Invest In Pieris

Details

Is Pieris Stock a good investment?

Details

What is Pieris Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Pieris Stock analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Stocks Directory Find actively traded stocks across global markets
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins

Is Pieris Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pieris Pharmaceuticals. If investors know Pieris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pieris Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(21.60)

Revenue Per Share

38.026

Quarterly Revenue Growth

(0.78)

Return On Assets

(0.15)

Return On Equity

(0.90)

The market value of Pieris Pharmaceuticals is measured differently than its book value, which is the value of Pieris that is recorded on the company's balance sheet. Investors also form their own opinion of Pieris Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pieris Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pieris Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pieris Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pieris Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pieris Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pieris Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pieris Ebitda vs Net Income From Continuing Ops Analysis

Ebitda vs Net Income From Continuing Ops

Ebitda vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Ebitda

Net Income From Continuing Ops

Pieris Pharmaceuticals fundamental ratios Correlations

Pieris Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pieris Pharmaceuticals fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Pieris Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Total Liab	+ 0.97	Total Assets
Total Current Assets	+ 0.97	Total Assets
Retained Earnings Total Equity	+ 0.97	Retained Earnings
Total Current Assets	+ 0.97	Cash And Short Term Investments

Cash	- 0.98	Net Debt
Retained Earnings Total Equity	- 0.94	Common Stock
Retained Earnings Total Equity	- 0.93	Common Stock Total Equity
Common Stock	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.92	Net Debt
Net Debt	- 0.9	Total Assets